Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 8/2007

01-08-2007 | Breast Oncology

Preoperative Lymphoscintigraphy Predicts the Successful Identification but Is Not Necessary in Sentinel Lymph Nodes Biopsy in Breast Cancer

Authors: Lei Wang, MD, Jin-ming Yu, MD, Yong-sheng Wang, MD, Wen-shu Zuo, Yan Gao, Jiang Fan, MD, Ji-yu Li, Xu-dong Hu, Ming-lu Chen, Guo-ren Yang, MD, Zheng-bo Zhou, Yan-song Liu, Yong-qing Li, Yan-bing Liu, Tong Zhao, Peng Chen

Published in: Annals of Surgical Oncology | Issue 8/2007

Login to get access

Abstract

Background

Although preoperative lymphoscintigraphy in sentinel lymph node biopsy (SLNB) for breast cancer patients is undergone commonly, its clinical significance remains controversial.

Methods

We retrospectively analyzed our database that contained 636 consecutive breast cancer patients who received preoperative lymphoscintigraphy before SLNB.

Results

The sentinel lymph nodes (SLNs) of 86.5% of patients were well imaged by lymphoscintigraphy, and SLN were located extra-axilla in 5.3% patients. The visualization of SLN in lymphoscintigraphy was not associated with histopathologic type, location, and stage of primary tumor, as well as the time interval from injection of radiocolloid to surgery. The negative lymphoscintigraphy results were associated with excision `biopsy before injection of radiocolloid and positive axillary node statues. The SLN was successfully detected in 625 (98.3%) enrolled patients. Failure of surgical identification of axillary SLN was associated with whether hot spot was imaged by lymphoscintigraphy. However, we identified axillary SLN in 90 (90.9%) out of 99 patients with negative axillary findings in lymphoscintigram. The false negative rate of SLNB in our study was 16.0% (15 of 94) among patients of training group, and there was no significant difference in the false negative rate between patients who had axillary hot spot in lymphoscintigram and those who had not (P = .273).

Conclusions

Visualization of SLN in preoperative lymphoscintigraphy predicted the successful SLN identification. However, it was less informative for the location of SLN during operation. Considering the complexity, time consumed, and cost, lymphoscintigraphy should at present be undergone for investigation purposes only.
Literature
1.
Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52:227–37PubMedCrossRef
2.
Wang Y, Yu J, Wang L, Liu J, Yang G, Liu Y. The study of sentinel node biopsy in clinical node negative breast cancer in China.. Breast Cancer Res Treat 2004; 88:S89CrossRef
3.
Cody HS, 3rd. Sentinel lymph node mapping in breast cancer. Oncology (Williston Park) 1999; 13:25–34; discussion 35–6, 39, 43
4.
Cox CE, Haddad F, Bass S, et al. Lymphatic mapping in the treatment of breast cancer. Oncology (Williston Park) 1998; 12:1283–92; discussion 1293–4, 1297–8
5.
Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998; 339:941–6PubMedCrossRef
6.
McMasters KM, Giuliano AE, Ross MI, et al. Sentinel-lymph-node biopsy for breast cancer—not yet the standard of care. N Engl J Med 1998; 339:990–5PubMedCrossRef
7.
Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91:368–73PubMedCrossRef
8.
Mudun A, Murray DR, Herda SC, et al. Early stage melanoma: lymphoscintigraphy, reproducibility of sentinel node detection, and effectiveness of the intraoperative gamma probe. Radiology 1996; 199:171–5PubMed
9.
Thompson JF, Uren RF, Shaw HM, McCarthy WH, Quinn MJ, O’Brien CJ, Howman-Giles RB. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg 1999; 189:195–204PubMedCrossRef
10.
Teal CB, Slocum JP, Akin EA, Kelly TA. Correlation of lymphoscintigraphy with the number of sentinel lymph nodes identified intraoperatively in patients with breast cancer. Am J Surg 2005; 190:567–9PubMedCrossRef
11.
Shoher A, Diwan A, Teh BS, Lu HH, Fisher R, Lucci A Jr. Lymphoscintigraphy does not enhance sentinel node identification or alter management of patients with early breast cancer. Curr Surg 2006; 63:207–12PubMedCrossRef
12.
McMasters KM, Wong SL, Tuttle TM, et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg 2000; 231:724–31PubMedCrossRef
13.
Marchal F, Rauch P, Morel O, et al. Results of preoperative lymphoscintigraphy for breast cancer are predictive of identification of axillary sentinel lymph nodes. World J Surg 2006; 30:55–62PubMedCrossRef
14.
Krynyckyi BR, Kim SC, Kim CK. Preoperative lymphoscintigraphy and triangulated patient body marking are important parts of the sentinel node process in breast cancer. World J Surg Oncol 2005; 3:56PubMedCrossRef
15.
Kim SC, Kim DW, Moadel RM, et al. Using the intraoperative hand held probe without lymphoscintigraphy or using only dye correlates with higher sensory morbidity following sentinel lymph node biopsy in breast cancer: a review of the literature. World J Surg Oncol 2005; 3:64PubMedCrossRef
16.
Goyal A, Newcombe RG, Mansel RE, et al. Role of routine preoperative lymphoscintigraphy in sentinel node biopsy for breast cancer. Eur J Cancer 2005; 41:238–43PubMedCrossRef
17.
Blessing WD, Stolier AJ, Teng SC, Bolton JS, Fuhrman GM. A comparison of methylene blue and lymphazurin in breast cancer sentinel node mapping. Am J Surg 2002; 184:341–5PubMedCrossRef
18.
Tuttle TM, Zogakis TG, Dunst CM, Zera RT, Singletary SE. A review of technical aspects of sentinel lymph node identification for breast cancer. J Am Coll Surg 2002; 195:261–8PubMedCrossRef
19.
Alazraki NP, Eshima D, Eshima LA, Herda SC, Murray DR, Vansant JP, Taylor AT. Lymphoscintigraphy, the sentinel node concept, and the intraoperative gamma probe in melanoma, breast cancer, and other potential cancers. Semin Nucl Med 1997; 27:55–67PubMedCrossRef
20.
De Cicco C, Cremonesi M, Luini A, et al. Lymphoscintigraphy and radioguided biopsy of the sentinel axillary node in breast cancer. J Nucl Med 1998; 39:2080–4PubMed
21.
Burak WE, Jr., Walker MJ, Yee LD, et al. Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer. Am J Surg 1999; 177:445–9PubMedCrossRef
22.
Upponi SS, McIntosh SA, Wishart GC, Balan KK, Purushotham AD. Sentinel lymph node biopsy in breast cancer—is lymphoscintigraphy really necessary? Eur J Surg Oncol 2002; 28:479–80PubMed
23.
Lawson LL, Sandler M, Martin W, Beauchamp RD, Kelley MC. Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy do not enhance the accuracy of lymphatic mapping for breast cancer. Am Surg 2004; 70:1050–5; discussion 1055–6PubMed
24.
Chagpar AB, Kehdy F, Scoggins CR, et al. Effect of lymphoscintigraphy drainage patterns on sentinel lymph node biopsy in patients with breast cancer. Am J Surg 2005; 190:557–62PubMedCrossRef
25.
Kawase K, Gayed IW, Hunt KK, et al. Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer. J Am Coll Surg 2006; 203:64–72PubMedCrossRef
26.
Rousseau C, Classe JM, Campion L, et al. The impact of nonvisualization of sentinel nodes on lymphoscintigraphy in breast cancer. Ann Surg Oncol 2005; 12:533–8PubMedCrossRef
27.
Dupont EL, Kamath VJ, Ramnath EM, et al. The role of lymphoscintigraphy in the management of the patient with breast cancer. Ann Surg Oncol 2001; 8:354–60PubMedCrossRef
28.
Martin RC, 2nd, Chagpar A, Scoggins CR, Edwards MJ, Hagendoorn L, Stromberg AJ, McMasters KM. Clinicopathologic factors associated with false-negative sentinel lymph-node biopsy in breast cancer. Ann Surg 2005; 241:1005–12; discussion 1012–5PubMedCrossRef
29.
Degnim AC, Oh K, Cimmino VM, Diehl KM, Chang AE, Newman LA, Sabel MS. Is blue dye indicated for sentinel lymph node biopsy in breast cancer patients with a positive lymphoscintigram? Ann Surg Oncol 2005; 12:712–7PubMedCrossRef
30.
Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006; 106:4–16PubMedCrossRef
31.
Carcoforo P, Sortini D, Feggi L, et al. Clinical and Therapeutic Importance of Sentinel Node Biopsy of the Internal Mammary Chain in Patients with Breast Cancer: A Single-Center Study with Long-Term Follow-Up. Ann Surg Oncol 2006; 13:1338–43PubMedCrossRef
32.
Hong J, Chog E, Soni N, Carmalt H, Gillett D, Spillane AJ. Extra-axillary sentinel node biopsy in the management of early breast cancer. Eur J Surg Oncol 2005; 31:942–8PubMedCrossRef
33.
Farrus B, Vidal-Sicart S, Velasco M, et al. Incidence of internal mammary node metastases after a sentinel lymph node technique in breast cancer and its implication in the radiotherapy plan. Int J Radiat Oncol Biol Phys 2004; 60:715–21PubMedCrossRef
34.
Allen B, Campbell I, Desai S, Dray M, Scarlet J. Pilot study comparing the accuracy of lymphoscintigraphy sentinel lymph node localisation with axillary node dissection in women with operable breast cancer. N Z Med J 2001; 114:233–6PubMed
35.
Klauber-DeMore N, Bevilacqua JL, Van Zee KJ, Borgen P, Cody HS 3rd. Comprehensive review of the management of internal mammary lymph node metastases in breast cancer. J Am Coll Surg 2001; 193:547–55PubMedCrossRef
Metadata
Title
Preoperative Lymphoscintigraphy Predicts the Successful Identification but Is Not Necessary in Sentinel Lymph Nodes Biopsy in Breast Cancer
Authors
Lei Wang, MD
Jin-ming Yu, MD
Yong-sheng Wang, MD
Wen-shu Zuo
Yan Gao
Jiang Fan, MD
Ji-yu Li
Xu-dong Hu
Ming-lu Chen
Guo-ren Yang, MD
Zheng-bo Zhou
Yan-song Liu
Yong-qing Li
Yan-bing Liu
Tong Zhao
Peng Chen
Publication date
01-08-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 8/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9418-4

Other articles of this Issue 8/2007

Annals of Surgical Oncology 8/2007 Go to the issue

Endocrine Tumors

The Negative Sestamibi Scan: Is a Minimally Invasive Parathyroidectomy Still Possible?

OriginalPaper

Heme Oxygenase-1 Gene Promoter Polymorphism is Associated with Risk of Gastric Adenocarcinoma and Lymphovascular Tumor Invasion

Editorial

Lymphatic Mapping and Sentinel Lymph Node Biopsy for Locally Recurrent Breast Cancer: New Clues to Understanding the Biology of Chest Wall Relapse

Melanomas

Reliability of Lymphatic Mapping After Wide Local Excision of Cutaneous Melanoma

Gastrointestinal Oncology

Critical Analysis of Treatment Failure After Complete Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Dissemination From Appendiceal Mucinous Neoplasms

Bone and Soft Tissue Sarcomas

Toxicity and Outcomes Associated with Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Sarcomatosis